Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Expands By 606.2%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 289,957 shares, a growth of 606.2% from the June 15th total of 41,058 shares. Based on an average trading volume of 18,514,293 shares, the short-interest ratio is currently 0.0 days. Currently, 8.5% of the company’s stock are sold short.

Institutional Trading of Catheter Precision

A hedge fund recently bought a new position in Catheter Precision stock. Millennium Management LLC bought a new stake in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision at the end of the most recent quarter. 20.34% of the stock is currently owned by institutional investors and hedge funds.

Catheter Precision Stock Down 30.7%

Shares of NYSEAMERICAN:VTAK traded down $0.35 during trading on Friday, hitting $0.79. The stock had a trading volume of 2,388,087 shares, compared to its average volume of 20,266,990. Catheter Precision has a 12 month low of $0.61 and a 12 month high of $4.94. The company has a market capitalization of $2.85 million, a PE ratio of -0.06 and a beta of -1.07. The firm’s fifty day moving average is $0.92 and its 200 day moving average is $1.32. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.35.

Catheter Precision (NYSEAMERICAN:VTAK) last released its quarterly earnings results on Monday, May 18th. The company reported ($1.39) earnings per share for the quarter, beating the consensus estimate of ($20.90) by $19.51. The company had revenue of $0.43 million for the quarter, compared to analyst estimates of $1.60 million. Catheter Precision had a negative return on equity of 76.51% and a negative net margin of 1,297.56%.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.